Pricing Log in Create free account
Friday 6 November 2026 Export HALO’s income statement to Excel — free account

Halozyme Therapeutics, Inc.

HALO Healthcare Biotechnology

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.

Revenue
+39.2%
EPS
+45.6%
Free cash flow
−58.6%
Total debt
+115.1%

Quarter to September 2026, against a year earlier

104.06 18.90 −15.37%
Market cap
$14.0B
P/E
29.5×
Fwd P/E
17.9×
Dividend yield
—
F-score
5/9
Altman Z
3.46
Beneish M
−2.59
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Halozyme Therapeutics, Inc. (HALO) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Halozyme Therapeutics, Inc. (HALO) trades at a EV/EBITDA of 22.6×. Over the past ten years it has ranged from 0.0× (September 2020) to 119× (December 2020); the current reading is higher than 79% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 19.2× 72.44%
FY2024 11.1× (23.07%)
FY2023 14.5× (45.67%)
FY2022 26.6× 31.01%
FY2021 20.3× (47.04%)
FY2020 38.4× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 29.4× —
FY2016 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 20.5× 32.85%
Jun 2026 15.4× 1.02%
Mar 2026 15.3× (20.46%)
Dec 2025 19.2× 67.58%
43 more quarters

Against its own ten years

Low 0.0× High 119×
Ten-year median 13.5×
Current reading's percentile 79

EV/EBITDA against peers

Company EV/EBITDA
KYMR Kymera Therapeutics, Inc. compare n/m
SMMT Summit Therapeutics PLC compare n/m
BBIO BridgeBio Pharma, Inc. compare n/m
JAZZ Jazz Pharmaceuticals PLC compare 15.2×
EXEL Exelixis, Inc. compare 15.6×
HALO Halozyme Therapeutics, Inc. 22.6×
TECH Bio-Techne Corp compare 32.3×
BMRN BioMarin Pharmaceutical Inc. compare 38.2×
ASND Ascendis Pharma A/S compare 49.5×
Biotechnology industry median 0.7×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on HALO